Xuehao Wang

机构：Academy of Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Chinese Academy of Medical Sciences Dermatology Hospital, Jiangsu Province Hospital, Nanjing Medical University, Academia Sinica, Nanjing University · ORCID：0000-0002-1166-2718

发表论文 50 篇 · 总被引 1852 次 · h-index 17

代表论文

• Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial (2022 · Journal for ImmunoTherapy of Cancer · 被引 218)
• Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition) (2022 · HepatoBiliary Surgery and Nutrition · 被引 203)
• How does green credit policy improve corporate social responsibility in China? An analysis based on carbon‐intensive listed firms (2022 · Corporate Social Responsibility and Environmental Management · 被引 57)
• Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma (2022 · BMC Cancer · 被引 47)
• Development and Validation of a Novel Model to Predict Regional Lymph Node Metastasis in Patients With Hepatocellular Carcinoma (2022 · Frontiers in Oncology · 被引 23)
• Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target (2025 · Clinical and Molecular Hepatology · 被引 14)